RLAYRelay Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+25% of shares).
Choppy, but holding above its 200-day average. Price is +32% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RLAY is trading
Relay Therapeutics, Inc. is +284% over the past year while the S&P 500 is +18%: 265 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +32%
vs 200-day average · a clear uptrend
- RSI (14)
- 48
RSI (14) · neutral
- Below its 52-week high
- 14%
Below its 52-week high
Details›
- Last close2026-10-09
- $17.88
- 1 monthS&P 500 +2.7%
- −5.4%
- 1 yearS&P 500 +18%
- +284%
- 5 yearsS&P 500 +88%
- −50%
- vs 50-day average$19.03
- −6.1%
- 52-week high
- $20.77
- 52-week low
- $4.38
- Annualised volatility
- 70%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$117M
| Year | Return |
|---|---|
| 2026 (year to date) | +111% |
| 2025 | +105% |
| 2024 | −63% |
| 2023 | −26% |
| 2022 | −51% |
| 2021 | −26% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +3.0% |
| Feb | 6 | 3 of 6 | −2.3% |
| Mar | 6 | 2 of 6 | −5.6% |
| Apr | 6 | 2 of 6 | −4.0% |
| May | 6 | 2 of 6 | −5.9% |
| Jun | 6 | 6 of 6 | +12% |
| Jul | 6 | 5 of 6 | +5.5% |
| Aug | 7 | 4 of 7 | −0.14% |
| Sep | 7 | 3 of 7 | +4.6% |
| Oct | 7 | 2 of 7 | −2.1% |
| Nov | 6 | 3 of 6 | +5.1% |
| Dec | 6 | 3 of 6 | −0.60% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.